Background: Recurrence following androgen-deprivation therapy is associated with adverse clinical outcomes in prostate cancer, but the cellular origins and molecular mechanisms underlying this process are poorly defined. We previously identified a population of castration-resistant luminal progenitor cells expressing Bmi1 in the normal mouse prostate that can serve as a cancer cell-of-origin. Here, we investigate the potential of Bmi1-expressing tumor cells that survive castration to initiate recurrence in vivo. Methods: We employed lineage retracing in Bmi1-Cre ER ; R26R-confetti; Pten f/f transgenic mice to mark and follow the fate of
Most advanced prostate cancers are initially dependent on androgen signaling for survival at the time of initial diagnosis (1), making androgen deprivation therapy (ADT) the standard treatment option for these patients (2) . However, failure of ADT is common, resulting in tumor recurrence as castration resistant prostate cancer (CRPC) (3, 4 ). An emerging model of resistance to ADT in prostate cancer, particularly to the more potent newer antiandrogen drugs such as enzalutamide and abiraterone, involves lineage plasticity or transdifferentiation (5) (6) (7) (8) . Epigenetic regulators and stem cell reprogramming factors including Sox2 and Ezh2 appear to play important roles in this process (5, 6) . However, there has been a paucity of studies that attempt to specifically follow the fate of malignant prostate cells in regressed tumors following castration in order to understand the cellular processes associated with the emergence of CRPC.
In prostate cancer, the polycomb repressor complex 1 protein Bmi1 has been implicated in promoting tumor progression, stemness, and chemoresistance (9) (10) (11) (12) (13) . We recently identified a population of luminal progenitors termed castration-resistant Bmi1-expressing cells (CARBs) in the mouse prostate that serve as a prostate cancer cell of origin (14) . We hypothesized that analogous castration-resistant Bmi1-expressing tumor cells (tumor CARBs) may exist in prostate cancer that could seed recurrence after ADT. We reasoned that use of an inducible Bmi1-Cre ER driver and lineage retracing with a multicolor reporter allele (R26R-confetti) could make lineage-marking of tumor CARBs in castrated tumors feasible.
Methods

Mouse Strains and Procedures
The following mouse strains were from Jackson Laboratory (Bar Harbor, ME): Bmi1Cre ER (15) , R26R-Confetti (16), and Pten f/f (17) .
General procedures for tamoxifen administration and surgical castration have been described previously (14) . All mouse studies were approved by the Northwestern University Institutional Animal Care and Use Committee. Additional details are in the Supplementary Methods (available online).
Tissue Recombination and Renal Capsule Grafting
Dissociation of prostate glands and renal capsule grafting were performed as described previously (14) , and additional details are in the Supplementary Methods (available online). For the PTC-209 (Selleckchem, Houston, TX) treatment, mice (n ¼ 6 per group) were administrated vehicle (5% DMSO in corn oil) or PTC-209 (60 mg/kg) by intraperitoneal injection daily for 7 or 21 consecutive days.
Histology and Immunofluorescence Staining
Prostates and grafts were processed and stained as described previously (14) . Additional details are in the Supplementary Methods (available online).
Human Prostate Cancer Data
Human prostate cancer data for benign prostate tissues (n ¼ 28), localized prostate cancers (n ¼ 59), metastatic CRPCs (n ¼ 35), CRPC-Adeno (n ¼ 25), and CRPC-NE (n ¼ 10) were obtained from previously published datasets (18, 19) . Gene expression data were downloaded from NCBI Geo (GEO accession no. GSE35988) (18) and cBioPortal (19) . Patient groups were classified as high Bmi1/Sox2 and low Bmi1/Sox2 expression by the median of both Bmi1 and Sox2 mRNA expression values of the study population. Patients whose tumors had both Bmi1 and Sox2 expressions above and below the median value were defined as a high Bmi1/Sox2 expression and low Bmi1/Sox2 expression, respectively. Patient survivals were assessed by the Kaplan-Meier method. P values were determined by log-rank test. P values for the frequency of patient samples with high Bmi1/Sox2 expression were determined by v 2 test.
Additional details on experimental methods and materials are in the Supplementary Methods (available online).
Statistical Analysis
Data are shown as mean (SD). Statistical significance was evaluated using a two-tailed Student t test, v 2 test, or Fisher's exact test. Survival plots were depicted as Kaplan-Meier curves. P < .05 was considered statistically significant.
Results
Evaluation of Recurrence in BC-Pten Transgenic Prostate Tumors
We first sought to determine if prostate tumors contain analogous "tumor CARBs" and their potential role in recurrence. To this end, we first examined the response of tumors in transgenic Bmi1-Cre ER ; Pten f/f mice (hereafter referred to as BC-Pten mice) to castration. In BC-Pten mice, Pten is specifically deleted in Bmi1-expressing cells by tamoxifen administration. Three months after tamoxifen treatment, mice were castrated and then serially analyzed at various time points for evidence of tumor regression and recurrence ( Figure 1A ). In intact mice 3 months post-tamoxifen induction, mice exhibited diffuse HGPIN/carcinoma with uniform upregulation of p-Akt, indicating Pten loss ( Figure 1B ). At 0.5 months after castration, tumors were noticeably shrunken accompanied by a substantial increase in apoptosis ( Figure 1 , B and C). Nonetheless, these regressed tumors retained foci of p-Aktþ tumor cells. Transgenic prostate tumors (n ¼ 17) regressed upon castration but uniformly recurred within 3 months. By 3 months postcastration, tumors had regrown with strong p-Akt expression indistinguishable from that in pre-castrate mice. These results indicate that althouh BC-Pten tumors respond to castration, they do retain a population of tumor cells that survive castration and drive recurrence. As Bmi1 is not exclusively expressed in the prostate epithelium, Pten deletion in non-prostate Bmi1-expressing cells in BCPten mice may confound our results, in addition to the increased morbidity in the mice due to tumors arising from other sites. To get around this limitation and to amplify the prostate samples, we used a tissue recombination strategy to rescue transgenic BC-Pten mouse prostates by regeneration as grafts in host mice ( Figure 1D ). As expected, castration resulted in regression of rescued BC-Pten prostate tumor grafts with a statistically significant increase in apoptotic cell death (14.2-fold, P ¼ .004) and a decrease in proliferation (0.33-fold, P ¼ .003) (Figure 1 , E-H). However, at 2 to 5 months postcastration, most grafts contained multifocal HGPIN/carcinoma with a progressive increase in p-Akt positive lesions and proliferation ( Figure 1 , E-H), which show several distinct molecular and biological features including p16
Ink4a protein levels and cellular senescence from primary tumors of intact mice (Supplementary Figure 1 , available online). Therefore, in this model, we designated tumors from mice at 0.5 months postcastration as "regressed tumors" and tumors from mice 2 months or later postcastration as "relapsed" or "recurrent."
Assessment of Cellular Heterogeneity in BC-Pten Tumors
Surprisingly, we noted that established tumors in BC-Pten mice were heterogeneous for Bmi1 expression, although all tumors are expected to have originated from Bmi1þ cells (Figure 2A ). This was not a consequence of spurious Pten deletion in Bmi1-cells due to lack of fidelity of the Bmi1Cre ER driver, as no Bmi1-cells were observed in p-Aktþ lesions 10 days posttamoxifen, while the number of Bmi1-pAktþ cells progressively increased from 1 to 3 months post-tamoxifen ( Figure 2B ). Furthermore, analysis of tumors in BC-Pten mice carrying the R26R-confetti allele, in which tamoxifen induction labels isolated Bmi1þ cells randomly with one of four Confetti colors encoded by the R26R-Confetti allele ( Figure 2C ), revealed the existence of both Bmi1þ and Bmi1-cells within single color Confetti-labeled 
Assessment of Sox2 in Regressed Tumors following Castration
Given previous findings that prostate cancer lineage plasticity in the context of Tp53 and Rb loss could be mediated by epigenetic reprogramming factors Ezh2 and Sox2 (5,6), we evaluated Sox2 and Ezh2 expression in our model following castration using immunofluorescence staining. Notably, Sox2þ cells increased dramatically in the regressed tumors compared with intact tumors and remained at high levels in recurrent tumors ( Figure 4G ), suggesting that the Bmi1þSox2þ fraction in regressed lesions may represent a slow-cycling cancer stem cell pool from which recurrence arises. Finally, in metastatic CRPC patients pretreated with hormone therapy (18) , high expression of BMI1 and SOX2 was associated with poor outcome ( Figure 4H ), and the frequency of samples with high BMI1/SOX2 expression progressively increased from normal to primary cancer to metastatic CRPC ( Figure 4I ) (18) and was higher still in CRPC-NE relative to CRPC-Adeno ( Figure 4J ) (19) . Altogether, these observations support the notion that upregulation of both BMI1 and SOX2 could be key contributing factors to recurrence after ADT. To more directly examine the cells that initiate tumor recurrence after castration, we employed lineage retracing in transgenic BC-Pten-R26R-confetti mice following the scheme shown in Supplementary Figure 6A (available online). The confetti allele allows "retracing" that could be used to monitor tumor recurrence in situ, because a second tamoxifen treatment can lead to switching of colors (ie, retracing) exclusively between red and cyan or yellow and green ( Figure 7A ). In this model, a second tamoxifen treatment was provided a month after castration to label Bmi1þ tumor cells, which can be retraced by a switch in the confetti color of an emerging subclone ( Figure 7B ) and followed by a quantification of clone size of retraced cells over time. Importantly, no spontaneously retraced cells were observed in p-Aktþ lesions of regressed prostate tumors in BC-Pten transgenic mice not treated with a second tamoxifen, but multiple retraced cells/clones of a distinct color were observed within parental clones in animals subjected to retracing for 2 months (Supplementary Figure 6 , B and C, available online). Comorbidity in transgenic BC-Pten mice in which Pten is deleted in Bmi1þ cells throughout the body precluded analysis of retraced cells/clones in larger numbers and at longer periods posttamoxifen. We therefore turned to our model of BC-Pten prostate grafts rescued by tissue recombination as renal grafts in SCID mice as shown in Figure 7C . It is crucial for proper interpretation of the retracing experiment that PTC-209 treatment starts after tamoxifen has been cleared from the body so that any observed effects on the expansion of retraced clones are not due to suppression of Bmi1-Cre ER recombination activity by PTC-209. A control experiment using Bmi1-Cre ER ; R26R-YFP transgenic mice showed that 1 day is enough for tamoxifen to be cleared to levels below which is sufficient to activate Bmi1-Cre ER activation (Supplementary Figure 7 , available online). We therefore started PTC-209 3 days after the last tamoxifen treatment in the aforementioned retracing experiment. In grafts from vehicle-treated animals, we observed 9.1% retracing events in p-Aktþ lesions (n ¼ 28 retracing events observed in 307 confetti tumor clones from 24 grafts). At 1 month after retracing, we observed only singly labeled retraced cells within tumor clones that switched colors ( Figure 7D 
Targeting Bmi11Sox21 Cells for Suppressing Tumor
Discussion
This study provides direct evidence for the existence of tumor CARBs that can serve as a source for prostate tumor recurrence.
One surprising finding from our study is our observation that BC-Pten tumors displayed a high degree of heterogeneity in Bmi1 expression in hormonally intact, regressed, and recurrent tumors despite that tumors were derived from Bmi1þ cells using the Bmi1-Cre ER driver. Notably, Bmi1þ tumor cells in castrated mice (ie, tumor CARBs) had lower rates of apoptosis than Bmi1-tumor cells, making them excellent candidates for the analysis of a cohort of metastatic CRPC patients pretreated with hormone therapy shows that the patients with high expression in both Bmi1 and Sox2 (high Bmi1/ Sox2, n ¼ 7) have poorer prognosis than patients with low expression in both genes (low Bmi1/Sox2, n ¼ 27). Data for this analysis were used from the Grasso prostate cancer dataset (NCBI GEO Database #: GSE35988) (18) . P values were determined by log-rank test. I) Frequency of cases with high Bmi1/Sox2 expression in benign pros- 
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We found increased Sox2 expression in BC-Pten prostate tumors following castration, concomitant with a phenotypic switch from luminal to basal-like cells in response to antiandrogen therapy. However, despite the reversion of recurrent tumors to a luminal phenotype, they retained high levels of Sox2 expression, indicating that this level of Sox2 expression is not sufficient to drive lineage plasticity. Nonetheless, these observations, together with reports of Sox2 upregulation in other models of antiandrogen therapy-resistant CRPC (23) (24) (25) , are consistent with a role for Sox2 in establishing recurrence. Most strikingly, almost all Sox2þ cells were detected within the Bmi1þ tumor CARBs fraction, and pharmacologic inhibition of the small molecule Bmi1 inhibitor PTC-209 effectively targeted both Bmi1þSox2þ cells and impaired castration-resistant tumor growth. Because both Sox2 and Bmi1 play important roles in cancer stem cells to maintain self-renewal and promote tumor drug resistance in multiple tumor types, simultaneous perturbation of Bmi1 and Sox2 could provide a potential therapeutic advantage leading to eradication of tumor-reinitiating cells. Previous studies have shown that targeting stem-cell-specific antigens by immune response may be important in tumor progression (26, 27) . Thus, exploiting the immune response against stem-cell antigens, such as Sox2 or Bmi1, may provide a therapy to prevent recurrence.
Because PTC-209 resulted in a marked decrease in Bmi1 expression, which was accompanied by a reduction in Sox2, we examined whether the ability of PTC-209 to downregulate Sox2 is mediated through Bmi1 inhibition. However, Bmi1 knockdown by small interfering RNA in human prostate cancer cell lines had no effects on Sox2 protein levels, suggesting that the effects of PTC-209 on Sox2 expression were not related to its repressive activity on Bmi1 (unpublished data YA Yoo and SA Abdulkadir). Because PTC-209 was identified as a compound targeting Bmi1 expression under posttranscriptional control of 5' and 3' untranslated regions, it is possible that PTC-209 may elicit its effect on Sox2 by directly regulating Sox2 translation through untranslated region-regulatory regions.
The R26R-confetti allele was successfully used to monitor the ability of tumor CARBs to initiate recurrence. A caveat of the R26R-confetti allele strategy is that spontaneous color conversion might occur even in the absence of tamoxifen induction, particularly in the setting of cancer with genomic instability. However, retraced cells were never observed in regressed prostate tumors without a second tamoxifen, indicating that there was no spontaneous color conversion in our cohort. We observed retraced cells coexpressing two colors, however, such as cyan and red, consistent with polyploidy of tumor cells, making it possible for a retracing recombination event to occur at one allele to express a new color while other allele(s) maintain the original color.
A limitation of our study is that we have not defined the relative roles of Bmi1 vs Sox2 in driving recurrence in this model. This will require further studies. Our results provide strong evidence to support the notion that castration-resistant Bmi1þSox2þ cells serve as the cells of origin for prostate tumor recurrence and that targeting Bmi1/Sox2-expressing tumor-reinitiating cells with PTC-209 could be an efficacious treatment for recurrent tumors with Pten loss.
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